Our overall goal in this program project is to understand the potential of ligands of the human immunodeficiency virus (HIV-1) gp120 envelope glycoprotein to inhibit virus entry. HIV-1 infection is initiated by entry of the virus into host cells. The entry process depends on initial attachment of virus with host, and the molecular components of this attachment process are known. HIV-1 cell recognition occurs through envelope proteins on the viral spike, a heterotrimer of the gp120/gp41 complex. The interactions between gp120 and cell receptors appear to play the central role in viral entry. Hence, the design of antagonists of gp120 interactions with cell receptors is the central objective of the Program Project. We will utilize a comprehensive, interdisciplinary, multi-group approach that will combine chemical synthesis, high-resolution structure determination, thermodynamic and kinetic binding analyses, cell infection analyses, recombinant protein production and mutagenic analyses and computational modeling. We have already demonstrated our capacity to utilize this comprehensive approach as a team, and believe our experiences so far along with current starting points arrived at in our studies will successfully lead to important advances in mechanistic understanding and productive approaches to HIV-1 entry inhibitors. The Program Project will have 5 overarching specific aims. (1) Identify novel compounds that interact with functionally important regions of the HIV-1 gp120 glycoprotein. (2) Define the binding sites of the compounds on the gp120 glycoprotein. (3) Elucidate the mechanism of inhibition of HIV-1 entry associated with the compounds. (4) Optimize gp120-binding compounds for antiviral potency. (5) Understand the impact of variation in the HIV-1 envelope glycoproteins on the antiviral efficacy of the compounds. We will accomplish these aims through 5 Projects and 2 Cores. Project 1: Structure analysis of HIV-1 entry inhibition (Hendrickson);Project 2: Peptide-inspired competitive and allosteric inhibitors of HIV-1 entry (Chaiken);Project 3: Discovery and synthesis of small molecule CD4-gp120 antagonists (Smith);Project 4: Assembly and inhibition thermodynamics (Freire);Project 5: Structure-based antagonism of HIV-1 envelope function in cell entry (Sodroski);Core A: Computational modeling (LaLonde);Core B: Protein technologies (Chaiken). This program project will examine the potential of small molecules to inhibit HIV-1 viral entry and will identify candidate inhibitors as potential antagonists for AIDS prevention and treatment. Since many viral proteins involved in disease pathogenesis exhibit the type of plasticity found for HIV-1 gp120, we believe that the approaches we develop for the gp120 system will provide experimental paradigms for prevention and treatment of other diseases as well.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
3P01GM056550-16S1
Application #
8497344
Study Section
Special Emphasis Panel (ZRG1-AARR-A (40))
Program Officer
Sakalian, Michael
Project Start
1997-08-01
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2013-07-31
Support Year
16
Fiscal Year
2012
Total Cost
$189,090
Indirect Cost
$21,959
Name
Drexel University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
002604817
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Espy, Nicole; Pacheco, Beatriz; Sodroski, Joseph (2017) Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor. Virology 508:90-107
Nguyen, Hanh T; Madani, Navid; Ding, Haitao et al. (2017) Evaluation of the contribution of the transmembrane region to the ectodomain conformation of the human immunodeficiency virus (HIV-1) envelope glycoprotein. Virol J 14:33
Afanador, Gustavo A; Guerra, Alfredo J; Swift, Russell P et al. (2017) A novel lipoate attachment enzyme is shared by Plasmodium and Chlamydia species. Mol Microbiol 106:439-451
Witt, Kristen C; Castillo-Menendez, Luis; Ding, Haitao et al. (2017) Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs. PLoS One 12:e0170672
Acharya, Kriti; Rashad, Adel A; Moraca, Francesca et al. (2017) Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664. Proteins 85:843-851
Pancera, Marie; Lai, Yen-Ting; Bylund, Tatsiana et al. (2017) Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nat Chem Biol 13:1115-1122
Prévost, Jérémie; Zoubchenok, Daria; Richard, Jonathan et al. (2017) Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. J Virol 91:
Pacheco, Beatriz; Alsahafi, Nirmin; Debbeche, Olfa et al. (2017) Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors. J Virol 91:
Herschhorn, Alon; Sodroski, Joseph (2017) An entry-competent intermediate state of the HIV-1 envelope glycoproteins. Receptors Clin Investig 4:
Ding, Shilei; Verly, Myriam M; Princiotto, Amy et al. (2017) Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. AIDS Res Hum Retroviruses 33:428-431

Showing the most recent 10 out of 139 publications